RAPP

Rapport Therapeutics Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Rapport Therapeutics sales and earnings growth
RAPP Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 89.56%
  • FCF Y/Y↓ -21.03%
Rapport Therapeutics gross and profit margin trends
RAPP Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -38.90%
Rapport Therapeutics net debt vs free cash flow
RAPP Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Rapport Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗